Pub Date : 2021-01-01DOI: 10.1007/978-3-030-62195-7
{"title":"Nuclear Cardiology: Basic and Advanced Concepts in Clinical Practice","authors":"","doi":"10.1007/978-3-030-62195-7","DOIUrl":"https://doi.org/10.1007/978-3-030-62195-7","url":null,"abstract":"","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74003909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.1007/978-3-030-62195-7_31
B. Amorim, Marcel Yanagihara Rigolon, C. Ramos
{"title":"Diagnosis of Pulmonary Embolism","authors":"B. Amorim, Marcel Yanagihara Rigolon, C. Ramos","doi":"10.1007/978-3-030-62195-7_31","DOIUrl":"https://doi.org/10.1007/978-3-030-62195-7_31","url":null,"abstract":"","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88079528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Triglyceride (TG) deposit cardiomyovasculopathy (TGCV) is a novel cardiovascular disorder and was recently encoded as an orphan disease in Europe (ORPHA code: 565612). Defective lipolysis results in TG accumulation in the myocardium and coronary arteries in TGCV. The myocardial washout rate (WR) of iodine-123-β-methyl iodophenyl-pentadecanoic acid (BMIPP) is an essential indicator to evaluate myocardial lipolysis in vivo. TGCV is classified into primary and idiopathic type with and without PNPLA2 mutation, respectively. Here, we present the clinical correlation perspectives of TGCV patients in Chiba, Japan, to increase the awareness of this orphan disease and facilitate its diagnosis. Methods: We enrolled 234 patients who underwent BMIPP scintigraphy between September 2015 and July 2019. The diagnosis of TGCV was made based on the criteria we reported previously. Blood smear tests were performed for TGCV classification. The distributions of TGCV in each comorbidity were investigated. Results: In total, 104 patients were diagnosed with definitive idiopathic TGCV (I-TGCV). They had various comorbid conditions, including heart failure with reduced ejection fraction and multivessel coronary artery disease requiring revascularization. Moreover, the serum TG levels in I-TGCV patients were not high, and there was no correlation between serum TG level and BMIPP WR (n=205, p-value=0.31), supporting the pathophysiological hypothesis of TGCV. Conclusion: I-TGCV patients showed multiple coexistence of coronary artery disease, heart failure of unknown etiology, or diabetes mellitus. For patients with such clinical characteristics, BMIPP scintigraphy and calculation of WR should be considered proactively for the diagnosis of TGCV.
{"title":"Correlation Perspectives for the Diagnosis of Idiopathic Triglyceride Deposit Cardiomyovasculopathy.","authors":"Hideyuki Miyauchi, Takashi Iimori, Keisuke Hoshi, Masayuki Ohyama, Ken-Ichi Hirano, Yoshio Kobayashi","doi":"10.17996/anc.20-00128","DOIUrl":"https://doi.org/10.17996/anc.20-00128","url":null,"abstract":"<p><p><i>Background</i>: Triglyceride (TG) deposit cardiomyovasculopathy (TGCV) is a novel cardiovascular disorder and was recently encoded as an orphan disease in Europe (ORPHA code: 565612). Defective lipolysis results in TG accumulation in the myocardium and coronary arteries in TGCV. The myocardial washout rate (WR) of iodine-123-<i>β</i>-methyl iodophenyl-pentadecanoic acid (BMIPP) is an essential indicator to evaluate myocardial lipolysis in vivo. TGCV is classified into primary and idiopathic type with and without <i>PNPLA2</i> mutation, respectively. Here, we present the clinical correlation perspectives of TGCV patients in Chiba, Japan, to increase the awareness of this orphan disease and facilitate its diagnosis. <i>Methods</i>: We enrolled 234 patients who underwent BMIPP scintigraphy between September 2015 and July 2019. The diagnosis of TGCV was made based on the criteria we reported previously. Blood smear tests were performed for TGCV classification. The distributions of TGCV in each comorbidity were investigated. <i>Results</i>: In total, 104 patients were diagnosed with definitive idiopathic TGCV (I-TGCV). They had various comorbid conditions, including heart failure with reduced ejection fraction and multivessel coronary artery disease requiring revascularization. Moreover, the serum TG levels in I-TGCV patients were not high, and there was no correlation between serum TG level and BMIPP WR (n=205, p-value=0.31), supporting the pathophysiological hypothesis of TGCV. <i>Conclusion</i>: I-TGCV patients showed multiple coexistence of coronary artery disease, heart failure of unknown etiology, or diabetes mellitus. For patients with such clinical characteristics, BMIPP scintigraphy and calculation of WR should be considered proactively for the diagnosis of TGCV.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133925/pdf/anc-6-33.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9398079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amyloidosis is a systemic disorder in which abnormal amyloid proteins deposit in body organs, leading to organ dysfunction and death. Cardiac amyloid deposition, causing a sort of restrictive cardiomyopathy and associated with increased risk of mortality. Most cases of cardiac amyloidosis are of either light chain or transthyretin type. Early and accurate diagnosis of cardiac amyloidosis may improve outcomes. However, diagnosis requires systematic approach including electrocardiography and biomarkers when encountered suspicious candidate. Diagnosis by multimodality noninvasive imaging have been substantially studied and established for differentiation from subtypes. Recent advance in the treatment of amyloidosis offers therapeutic monitoring and prognosis.
{"title":"Cardiac Amyloidosis: Current Diagnostic Strategies Using Multimodality Imaging.","authors":"Kenji Fukushima, Shintaro Nakano, Ichiro Matsunari","doi":"10.17996/anc.20-00130","DOIUrl":"https://doi.org/10.17996/anc.20-00130","url":null,"abstract":"<p><p>Amyloidosis is a systemic disorder in which abnormal amyloid proteins deposit in body organs, leading to organ dysfunction and death. Cardiac amyloid deposition, causing a sort of restrictive cardiomyopathy and associated with increased risk of mortality. Most cases of cardiac amyloidosis are of either light chain or transthyretin type. Early and accurate diagnosis of cardiac amyloidosis may improve outcomes. However, diagnosis requires systematic approach including electrocardiography and biomarkers when encountered suspicious candidate. Diagnosis by multimodality noninvasive imaging have been substantially studied and established for differentiation from subtypes. Recent advance in the treatment of amyloidosis offers therapeutic monitoring and prognosis.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133936/pdf/anc-6-67.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9449495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In this report, several issues relevant to scientific publishing in the field of medical imaging are described. How the quality of the research in medical imaging is evaluated is presented as well. The need for journals and the role of current metrics to judge the quality of articles and journals are discussed. Several recommendations are given to aspiring authors on how to write scientific articles in this field to help them optimize their chances of having their articles accepted. Recommendations on how to effectively deal with the review process and how to properly communicate with scientific journals are offered in order to facilitate authors' interaction with reviewers and editors of the journals in the field.
{"title":"How to Write a Successful Article.","authors":"Ignasi Carrió","doi":"10.17996/anc.20-00127","DOIUrl":"https://doi.org/10.17996/anc.20-00127","url":null,"abstract":"<p><p>In this report, several issues relevant to scientific publishing in the field of medical imaging are described. How the quality of the research in medical imaging is evaluated is presented as well. The need for journals and the role of current metrics to judge the quality of articles and journals are discussed. Several recommendations are given to aspiring authors on how to write scientific articles in this field to help them optimize their chances of having their articles accepted. Recommendations on how to effectively deal with the review process and how to properly communicate with scientific journals are offered in order to facilitate authors' interaction with reviewers and editors of the journals in the field.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133931/pdf/anc-6-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9449494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Non-invasive cardiac imaging modalities including single-photon emission computed tomography myocardial perfusion image (SPECT-MPI) and coronary computed tomography angiography (CTA) have been widely used for diagnosis of coronary artery disease (CAD). The American Society of Nuclear Cardiology and Society of Cardiovascular Computed Tomography have recently published the guidelines for the instrumentation, acquisition, processing, interpretation, as well as reporting of SPECT and coronary CTA. These guidelines have highlighted and well documented how the imaging reporting influences medical practice for physician and treatment care for patients, suggesting that cardiac imaging reports for interpretation for patient management. This review article here summarizes improving quality of cardiac imaging reports by SPECT-MPI and coronary CTA.
{"title":"Improving Quality of Clinical Diagnosis Report with Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging and Coronary Computed Tomography Angiography.","authors":"Rine Nakanishi, Hidenobu Hashimoto, Takanori Ikeda","doi":"10.17996/anc.20-00111","DOIUrl":"https://doi.org/10.17996/anc.20-00111","url":null,"abstract":"<p><p>Non-invasive cardiac imaging modalities including single-photon emission computed tomography myocardial perfusion image (SPECT-MPI) and coronary computed tomography angiography (CTA) have been widely used for diagnosis of coronary artery disease (CAD). The American Society of Nuclear Cardiology and Society of Cardiovascular Computed Tomography have recently published the guidelines for the instrumentation, acquisition, processing, interpretation, as well as reporting of SPECT and coronary CTA. These guidelines have highlighted and well documented how the imaging reporting influences medical practice for physician and treatment care for patients, suggesting that cardiac imaging reports for interpretation for patient management. This review article here summarizes improving quality of cardiac imaging reports by SPECT-MPI and coronary CTA.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133933/pdf/anc-6-86.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarcoidosis, a multi-organ inflammatory condition commonly involving the heart and leading to high morbidity and mortality, is increasingly prevalent. PET imaging with 18F-FDG in conjunction with perfusion imaging is increasingly used for diagnosis, disease characterization, and to guide and follow treatment. However, various challenges remain with regard to protocols, interpretation of image findings, and how best to use test results to guide and monitor therapy. Further investigations of the testing technique, as well as better understanding of disease pathophysiology, are needed for better image utility in order to effectively improve patient outcome.
{"title":"Radionuclide Imaging for Cardiac Sarcoidosis: Much Potential Benefit, but Still Much to Do.","authors":"Mark I Travin","doi":"10.17996/anc.20-00115","DOIUrl":"https://doi.org/10.17996/anc.20-00115","url":null,"abstract":"<p><p>Sarcoidosis, a multi-organ inflammatory condition commonly involving the heart and leading to high morbidity and mortality, is increasingly prevalent. PET imaging with <sup>18</sup>F-FDG in conjunction with perfusion imaging is increasingly used for diagnosis, disease characterization, and to guide and follow treatment. However, various challenges remain with regard to protocols, interpretation of image findings, and how best to use test results to guide and monitor therapy. Further investigations of the testing technique, as well as better understanding of disease pathophysiology, are needed for better image utility in order to effectively improve patient outcome.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133935/pdf/anc-6-53.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Myocardial 18F-fluorodeoxyglucose (18F-FDG) uptake is a sign of active inflammation in patients with cardiac sarcoidosis (CS) under the correct circumstance. However, even under the proper preparation, diffuse myocardial 18F-FDG uptake is frequently observed in the failing heart and misleads the CS disease activity. The aim of this study was to establish the diagnostic value of resting myocardial perfusion single photon emission computed tomography (SPECT) for assessing CS disease activity in patients with diffuse myocardial 18F-FDG uptake. Methods: We examined 39 patients with either histologically or clinically proven CS. All patients underwent 18F-FDG positron emission tomography (PET) and resting 99mTc-SPECT. The presence of perfusion-metabolic mismatch was evaluated with generating polar maps of 18F-FDG PET and 99mTc-SPECT images. Results: Increased myocardial 18F-FDG uptake was observed in 33 (85%) of 39 patients. Focal 18F-FDG uptake was detected in 16 patients and diffuse 18F-FDG uptake was seen in 17 patients. Brain natriuretic peptide (BNP) levels were significantly higher in patients with diffuse 18F-FDG uptake than those with focal 18F-FDG uptake (p=0.002). With comparing polar maps of 18F-FDG PET and 99mTc-SPECT images, 8 of 16 patients with diffuse 18F-FDG uptake and myocardial perfusion defects demonstrated perfusion-metabolic mismatch which represented active inflammatory lesions in CS. Conclusions: Simultaneous evaluation of myocardial 18F-FDG PET and 99mTc-SPECT by polar map analysis provides more relevant information for assessing disease activity in CS than 18F-FDG PET images alone. Perfusion-metabolic mismatch might indicate latent active inflammation in CS patients with diffuse myocardial 18F-FDG uptake, who had advanced heart failure.
{"title":"Assessing the Clinical Value of Myocardial Perfusion SPECT in Cardiac Sarcoidosis with Diffuse Myocardial <sup>18</sup>F-FDG Uptake.","authors":"Emi Tateishi, Keisuke Kiso, Tetsuya Fukuda","doi":"10.17996/anc.20-00125","DOIUrl":"https://doi.org/10.17996/anc.20-00125","url":null,"abstract":"<p><p><i>Background</i>: Myocardial <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) uptake is a sign of active inflammation in patients with cardiac sarcoidosis (CS) under the correct circumstance. However, even under the proper preparation, diffuse myocardial <sup>18</sup>F-FDG uptake is frequently observed in the failing heart and misleads the CS disease activity. The aim of this study was to establish the diagnostic value of resting myocardial perfusion single photon emission computed tomography (SPECT) for assessing CS disease activity in patients with diffuse myocardial <sup>18</sup>F-FDG uptake. <i>Methods</i>: We examined 39 patients with either histologically or clinically proven CS. All patients underwent <sup>18</sup>F-FDG positron emission tomography (PET) and resting <sup>99m</sup>Tc-SPECT. The presence of perfusion-metabolic mismatch was evaluated with generating polar maps of <sup>18</sup>F-FDG PET and <sup>99m</sup>Tc-SPECT images. <i>Results</i>: Increased myocardial <sup>18</sup>F-FDG uptake was observed in 33 (85%) of 39 patients. Focal <sup>18</sup>F-FDG uptake was detected in 16 patients and diffuse <sup>18</sup>F-FDG uptake was seen in 17 patients. Brain natriuretic peptide (BNP) levels were significantly higher in patients with diffuse <sup>18</sup>F-FDG uptake than those with focal <sup>18</sup>F-FDG uptake (p=0.002). With comparing polar maps of <sup>18</sup>F-FDG PET and <sup>99m</sup>Tc-SPECT images, 8 of 16 patients with diffuse <sup>18</sup>F-FDG uptake and myocardial perfusion defects demonstrated perfusion-metabolic mismatch which represented active inflammatory lesions in CS. <i>Conclusions</i>: Simultaneous evaluation of myocardial <sup>18</sup>F-FDG PET and <sup>99m</sup>Tc-SPECT by polar map analysis provides more relevant information for assessing disease activity in CS than <sup>18</sup>F-FDG PET images alone. Perfusion-metabolic mismatch might indicate latent active inflammation in CS patients with diffuse myocardial <sup>18</sup>F-FDG uptake, who had advanced heart failure.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133934/pdf/anc-6-39.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9398082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Takayasu arteritis (TAK) is classified as large-vessel vasculitis caused by inflammation. It is often difficult to identify on clinical examination, and 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) plays an indispensable role in diagnosing TAK by detecting the location and grade of the inflammatory lesions. The clinical utility of 18F-FDG PET has been established by clinical evidence, and 18F-FDG PET was added to the Japanese national health insurance listing in April 2018. In TAK, 18F-FDG uptake shows typical findings and is easily distinguished, except from physiological uptake. Particularly, the clinical significance of 18F-FDG PET is that can present not only with stenosis but also without stenosis in the arteries, which means that therapeutic intervention is possible before irreversible stenosis develops in the arteries. Additionally, 18F-FDG PET has superior diagnostic accuracy because it allows quantitative analysis using the maximum standardized uptake value. The analysis is used for the assessment of disease activity of TAK and can be utilized for therapeutic intervention in case of repeating remission during the follow-up term.
{"title":"Diagnostic Role and Feasibility of <sup>18</sup>F-FDG PET for Assessing Takayasu Arteritis: Diagnostic Efficacy of Quantifying <sup>18</sup>F-FDG Uptake.","authors":"Daisuke Tezuka, Yasuhiro Maejima, Tetsuo Sasano, Mitsuaki Isobe","doi":"10.17996/anc.20-00116","DOIUrl":"https://doi.org/10.17996/anc.20-00116","url":null,"abstract":"<p><p>Takayasu arteritis (TAK) is classified as large-vessel vasculitis caused by inflammation. It is often difficult to identify on clinical examination, and <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET) plays an indispensable role in diagnosing TAK by detecting the location and grade of the inflammatory lesions. The clinical utility of <sup>18</sup>F-FDG PET has been established by clinical evidence, and <sup>18</sup>F-FDG PET was added to the Japanese national health insurance listing in April 2018. In TAK, <sup>18</sup>F-FDG uptake shows typical findings and is easily distinguished, except from physiological uptake. Particularly, the clinical significance of <sup>18</sup>F-FDG PET is that can present not only with stenosis but also without stenosis in the arteries, which means that therapeutic intervention is possible before irreversible stenosis develops in the arteries. Additionally, <sup>18</sup>F-FDG PET has superior diagnostic accuracy because it allows quantitative analysis using the maximum standardized uptake value. The analysis is used for the assessment of disease activity of TAK and can be utilized for therapeutic intervention in case of repeating remission during the follow-up term.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133926/pdf/anc-6-74.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sarcoidosis is a significant disease affecting the heart. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well-validated method for identifying significant focal inflammatory sarcoid lesions. The recent progress in image interpretation in nuclear medicine improves the diagnosis and the risk stratification in patients with cardiac sarcoidosis. Especially, metabolic activity, texture analysis, phase analysis, right ventricle assessment, and digital PET/CT are promising methods to assess cardiac sarcoidosis. This review focuses on the latest data analyses and image interpretation used in nuclear medicine to assess cardiac sarcoidosis.
{"title":"Nuclear Medicine Image Interpretation Progress in the Assessment of Cardiac Sarcoidosis: July 2019 ASNC/JSNC Joint Session.","authors":"Masanao Naya, Osamu Manabe","doi":"10.17996/anc.20-00113","DOIUrl":"https://doi.org/10.17996/anc.20-00113","url":null,"abstract":"<p><p>Sarcoidosis is a significant disease affecting the heart. <sup>18</sup>F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well-validated method for identifying significant focal inflammatory sarcoid lesions. The recent progress in image interpretation in nuclear medicine improves the diagnosis and the risk stratification in patients with cardiac sarcoidosis. Especially, metabolic activity, texture analysis, phase analysis, right ventricle assessment, and digital PET/CT are promising methods to assess cardiac sarcoidosis. This review focuses on the latest data analyses and image interpretation used in nuclear medicine to assess cardiac sarcoidosis.</p>","PeriodicalId":72228,"journal":{"name":"Annals of nuclear cardiology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10133950/pdf/anc-6-49.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9393121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}